Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.42 |
| ▸ | LOX | P28300 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 2/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.37 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.37 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5700160 | 0.80 | SYK (0.47) | HRH4NR1H2NR1H3LOXL2LOX | |
| SCHEMBL30015071 | 0.77 | SMARCA2 (0.46) | LOXL2LOXARKCNQ2SMARCA2 | |
| SCHEMBL15454569 | 0.77 | SMARCA2 (0.46) | LOXL2LOXARKCNQ2SMARCA2 | |
| SCHEMBL2566196 | 0.77 | LOXL2 (0.46) | LOXL2LOXARKCNQ2SMARCA2 | |
| SCHEMBL29529396 | 0.75 | TRPV4 (0.47) | HRH4NR1H2NR1H3FEN1KDM5B | |
| SCHEMBL17694102 | 0.75 | HRH4 (0.38) | HRH4NR1H2NR1H3RIPK1 | |
| Hydrochloric Acid SCHEMBL27991102 | 0.75 | LOXL2 (0.47) | LOXL2LOXARKCNQ2SMARCA2 | |
| SCHEMBL10060473 | 0.71 | CA2 (0.48) | NR1H2NR1H3 | |
| SCHEMBL179263 | 0.71 | LOXL2 (0.47) | LOXL2LOXARSMARCA2SMARCA4 | |
| SCHEMBL2629467 | 0.70 | CA1 (0.56) | ARMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210353610-A1 | SMALL MOLECULE MENIN INHIBITORS | SERVIER PHARMACEUTICALS LLC | 2021-11-18 | — | — | US | disclosed |
| US-20210198237-A1 | PIPERIDINES AS MENIN INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2021-07-01 | — | — | US | disclosed |
| US-11045448-B2 | Piperidines as covalent menin inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-06-29 | — | — | US | disclosed |
| US-20210115018-A1 | PIPERIDINE COMPOUNDS AS COVALENT MENIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-04-22 | — | — | US | disclosed |
| US-20190152947-A1 | PIPERIDINES AS MENIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353610-A1 | SMALL MOLECULE MENIN INHIBITORS | MEN1, BRCA1, KRAS | HRH4 1713/4885NR1H2 4252/4885NR1H3 4417/4885 |
| US-20210198237-A1 | PIPERIDINES AS MENIN INHIBITORS | MEN1, WFS1, BRCA1 | HRH4 964/4885NR1H2 4174/4885NR1H3 4340/4885 |
| US-20210115018-A1 | PIPERIDINE COMPOUNDS AS COVALENT MENIN INHIBITORS | MEN1, BRCA1, PRMT1 | HRH4 1151/4885NR1H2 4385/4885NR1H3 4596/4885 |
| US-20190152947-A1 | PIPERIDINES AS MENIN INHIBITORS | MEN1, GDI2, GNAQ | HRH4 655/4885NR1H2 4164/4885NR1H3 4383/4885 |
| US-11045448-B2 | Piperidines as covalent menin inhibitors | MEN1, H1-10, HDAC10 | HRH4 637/4885NR1H2 4295/4885NR1H3 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.